share_log

Coherus BioSciences to Divest Udenyca to Intas Pharmaceuticals for Up to $558 Million

Coherus BioSciences to Divest Udenyca to Intas Pharmaceuticals for Up to $558 Million

coherus biosciences將Udenyca出售給Intas製藥,交易金額高達55800萬美元
MT Newswires ·  2024/12/03 20:47

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論